Analyst Group

Analyst Group Comment on Circio’s Big Pharma Feasibility Study Progressing to In Vivo Testing

Källa: MFN
Positiv

Sammanfattning

Circio Holding ASA meddelar att en studie med ett stort läkemedelsbolag har gått vidare till in vivo-tester. Studien, som utvärderar circVec-AAV genterapi för CNS-indikationer, är fullt finansierad av läkemedelsbolaget. Framstegen bekräftar samarbetets fortskridande och partnerns engagemang.

Analys

Framstegen till in vivo-tester är en positiv milstolpe som bekräftar att samarbetet med läkemedelsbolaget fortskrider enligt plan. Detta steg är en teknisk förutsättning för den kommande utvärderingen av circVec i CNS-indikationer. Med en säkrad finansiell runway in i 2030, efter den nyligen genomförda kapitalanskaffningen, är Circio väl positionerat för framtida licensdiskussioner.

Insikter

  • • Framstegen till in vivo-tester är en viktig teknisk milstolpe som banar väg för framtida utvärderingar.
  • • Den finansiella styrkan efter kapitalanskaffningen ger Circio en förhandlingsfördel inför kommande licensavtal.
  • • Nästa strategiskt viktiga händelse är uppdateringen av det partnerfinansierade projektet under Q4-2026.

Circio Holding ASA (”Circio” or ”the Company”) announced, on the 24th of April 2026, that the fully funded feasibility study with a major global pharmaceutical company, originally entered in November 2025, has advanced from in vitro to in vivo testing. The study evaluates circVec-AAV gene therapy within a CNS indication, is fully funded by the pharmaceutical partner, and contains no downstream rights or obligations on either side.

Circio Holding ASA (”Circio” or ”the Company”) announced, on the 24th of April 2026, that the fully funded feasibility study with a major global pharmaceutical company, originally entered in November 2025, has advanced from in vitro to in vivo testing. The study evaluates circVec-AAV gene therapy within a CNS indication, is fully funded by the pharmaceutical partner, and contains no downstream rights or obligations on either side.

In summary, Analyst Group views the progression to in vivo testing as a positive incremental milestone that confirms the collaboration is advancing on schedule and that the partner remains committed to evaluating circVec in CNS. The Q4-26 Partnered project update remains the more strategically decisive event for the collaboration and, by extension, for Analyst Group’s modelled first AAV-circVec licensing agreement, with the in vivo step serving as the necessary technical bridge to that readout. With the financial runway secured into 2030 following the recently completed NOK 250m private placement, Circio is also positioned to enter any subsequent licensing discussions from a position of strength rather than financial pressure, providing a strong foundation for the negotiations to come.

Read Analyst Group’s comment here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.Read more about Analyst Group This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.